Recombinant Human Insulin Market Size, Share, Trends, Growth 2032

Recombinant Human Insulin Industry Prospective:

The global recombinant human insulin market size was worth around USD 19.5 billion in 2023 and is predicted to grow to around USD 26.5 billion by 2032 with a compound annual growth rate (CAGR) of roughly 3.5% between 2024 and 2032.

Request Free Sample

Recombinant Human Insulin Market: Overview

A synthetic version of insulin generated by recombinant DNA processing is recombinant human insulin. Its structure is like the insulin created in the human pancreas naturally. This type of insulin is produced by introducing the human insulin gene into yeast (Saccharomyces cerevisiae) or Escherichia coli, insulin producers.

Often used to treat diabetes mellitus, recombinant human insulin helps control blood glucose levels in people whose systems either cannot use it efficiently or create enough insulin. By making insulin more generally available, enhancing safety, and providing tailored treatment options, it transformed the treatment of those with diabetes.

Key Insights

• As per the analysis shared by our research analyst, the global recombinant human insulin market is estimated to grow annually at a CAGR of around 3.5% over the forecast period (2024-2032).
• In terms of revenue, the global recombinant human insulin market size was valued at around USD 19.5 billion in 2023 and is projected to reach USD 26.5 billion by 2032.
• The increasing R&D investment is expected to drive the recombinant human insulin market over the forecast period.
• Based on drug, the short-acting human insulin segment is expected to dominate the recombinant human insulin market over the forecast period.
• Based on brand, the insuman segment is expected to hold the largest market share over the forecast period.
• Based on distribution channel, the hospital segment is expected to hold the largest market share over the forecast period.
• Based on region, North America is expected to dominate the market during the forecast period.

Recombinant Human Insulin Market: Growth Drivers

Rising prevalence of diabetes drives market growth

Treatment and control of diabetes, a chronic metabolic disorder marked by raised blood sugar levels, depend critically on human insulin. Among its several applications are those of insulin replacement, individualized treatment, and disease management. The broad use of the medication in treating type 1 diabetes—which supplies the insulin the body cannot generate on its own to assist in regulating blood sugar levels and prevent hyperglycemia—is also supporting the recombinant human insulin market growth. It is also given orally to boost insulin output and help the body to absorb glucose.

Furthermore, the growing use of products in insulin pump treatment—which offers a continuous supply of insulin throughout the day to replicate the basal insulin secretion of a normal pancreas—is driving the development of the market. Human insulin is also essential in preoperative and critical care environments to prevent glucose fluctuations and lower surgical complication risk.

Recombinant Human Insulin Market: Restraints

The high cost of insulin hinders market growth

One of the main obstacles to the worldwide insulin industry is the high price of recombinant human insulin, which has an especially negative effect on patient access and market dynamics. This problem is particularly pertinent in both developed and developing countries, where managing diabetes is significantly hampered by the availability and price of insulin.

Significant funding is needed for research, clinical studies, and regulatory approval procedures to manufacture recombinant human insulin. The eventual price of the product frequently reflects these large upfront expenses. Insulin is expensive because pharmaceutical companies invest years in thorough testing to guarantee its efficacy and safety. Therefore, the high cost of insulin might hinder the recombinant human insulin market during the projected period.

Recombinant Human Insulin Market: Opportunities

The rising number of contracts offers a lucrative opportunity for market growth

The rising number of contracts is expected to offer a lucrative opportunity for the recombinant human insulin market over the analysis period. For instance, in April 2022, A subsidiary of Biocon Ltd., Biocon Biologics Limited (BBL), announced that the Ministry of Health (MoH) in Malaysia has given its subsidiary Biocon Sdn. Bhd. a three-year contract worth USD 90 million* (MYR 375 million) for its recombinant human insulin brand Insugen®.

As a subsidiary of Duopharma Biotech, one of Malaysia's top pharmaceutical and biotech companies, Biocon Sdn. Bhd. will produce and supply its line of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg). Patients will have access to Biocon Biologics' Insugen formulations at all Ministry of Health hospitals, district health offices, and clinics.

Recombinant Human Insulin Market: Challenges

The availability of alternative treatments poses a major challenge to market expansion

One significant factor impeding the growth of the recombinant human insulin industry is the availability of alternative treatments. Treatment preferences change as a result of these alternatives, which give diabetic patients additional choices, some of which are better than insulin therapy.

For Type 2 diabetes, metformin, sulfonylureas, and other oral anti-diabetic medication groups are frequently utilized as first-line therapies. Because of their affordability, non-invasiveness, and convenience of use in comparison to insulin therapy, these drugs are frequently chosen.

Furthermore, drugs like dulaglutide, semaglutide, and liraglutide have become more well-liked due to their ability to manage blood sugar levels and aid in weight loss. These medications, which are administered subcutaneously, either weekly or daily, eliminate the need for numerous daily injections and are less likely to cause hypoglycemia than insulin.

Recombinant Human Insulin Market: Report Scope

Recombinant Human Insulin Market: Segmentation

The global recombinant human insulin industry is segmented based on drug, brand, distribution channel, and region.

Based on the drug, the global recombinant human insulin market is segmented into short-acting human insulin, intermediate-acting human insulin, and premixed human insulin. The short-acting human insulin segment is expected to dominate the recombinant human insulin market over the forecast period. One of the main factors driving growth is the incidence of diabetes mellitus worldwide. The International Diabetes Federation (IDF) projects that by 2045, there will be 783 million diabetics worldwide. The market is growing as a direct result of the increased need for insulin therapy, including short-acting versions.

Based on brand, the global recombinant human insulin industry is bifurcated into insuman, humulin, Novolin, and other brands. The insuman segment is expected to hold the largest market share over the forecast period. In markets where the affordability of recombinant insulin outweighs that of premium analog options, insuman products are frequently chosen. This is particularly important in sections of Eastern Europe, Southeast Asia, and Sub-Saharan Africa.

Based on the distribution channel, the global recombinant human insulin market is bifurcated into hospitals, retail pharmacies, online pharmacies, and others. The hospital segment is expected to hold the largest market share over the forecast period. Complications such as diabetic ketoacidosis (DKA), hyperglycemia, and hypoglycemia account for a large portion of diabetes-related hospital admissions. In emergency treatment, recombinant human insulin is commonly utilized to quickly stabilize blood sugar levels.

Recombinant Human Insulin Market: Regional Analysis

North America dominates the market over the projected period

North America is expected to dominate the global recombinant human insulin market. This is largely due to the growing number of market players and the incidence of diabetes in this region. Diabetes is one of the chronic conditions whose rate of development in the US is the fastest. Every year, over 1.75 million Americans are diagnosed with diabetes. Also highest in the country is the obesity rate, a main factor causing type-2 diabetes.

While over 28% of Americans go untreated, 86% of American adults have blood glucose levels that considerably increase their chance of developing diabetes in the next years. The number of adults with diabetes has more than doubled as the American population ages and gets more obese or overweight over the past 20 years. The increasing demand for diabetes therapies resulting from the rising diabetic population in this country is helping the US market under research to grow.

Recombinant Human Insulin Market: Competitive Analysis

The global recombinant human insulin market is dominated by players like:

• Biocon
• Eli Lilly and Company
• Zhuhai United Laboratories Co Ltd.
• Dongbao Enterprise Group Co Ltd.
• Sanofi S.A.
• Novo Nordisk A/S
• Gan & Lee Pharmaceuticals Ltd.
• Bioton S.A.
• Julphar Gulf Pharmaceutical Industries
• Wanbang Biopharmaceuticals Co Ltd

The global recombinant human insulin market is segmented as follows:

By Drug

• Short-acting Human Insulin
• Intermediate-acting Human Insulin
• Premixed Human Insulin

By Brand

• Insuman
• Humulin
• Novolin
• Other Brands

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa